Head to Head Comparison: Patheon (PTHN) & The Competition
Patheon (NYSE: PTHN) is one of 102 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Patheon to similar businesses based on the strength of its institutional ownership, valuation, analyst recommendations, risk, profitability, earnings and dividends.
This table compares Patheon and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent ratings and target prices for Patheon and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Patheon presently has a consensus target price of $33.60, indicating a potential downside of 3.95%. As a group, “Pharmaceuticals” companies have a potential upside of 18.44%. Given Patheon’s competitors stronger consensus rating and higher probable upside, analysts plainly believe Patheon has less favorable growth aspects than its competitors.
Valuation & Earnings
This table compares Patheon and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Patheon||$1.87 billion||$31.70 million||46.03|
|Patheon Competitors||$8.17 billion||$1.09 billion||134.76|
Patheon’s competitors have higher revenue and earnings than Patheon. Patheon is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Institutional and Insider Ownership
0.6% of Patheon shares are owned by institutional investors. Comparatively, 43.9% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 0.1% of Patheon shares are owned by insiders. Comparatively, 11.3% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Patheon competitors beat Patheon on 9 of the 12 factors compared.
Patheon N.V. is a provider of outsourced pharmaceutical development and manufacturing services. The Company’s segments include Drug Product Services (DPS), Pharmaceutical Development Services (PDS) and Drug Substance Services (DSS). The DPS segment is engaged in manufacturing and packaging for approved prescription, over-the-counter (OTC) and nutritional products. The PDS segment provides a range of formulation, production and technical services from the early stages of a product’s development to regulatory approval, as well as for new formulations of approved products for lifecycle extension. The DSS segment provides small molecule active pharmaceutical ingredient (API) and outsourced manufacturing solutions for large molecule biological API from early development through commercial scale production. It provides an integrated range of API and finished drug product services to its customers, from formulation development to clinical and commercial-scale manufacturing.
Receive News & Ratings for Patheon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Patheon and related companies with Analyst Ratings Network's FREE daily email newsletter.